Totonchy Mariam, Leffell David
Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208059, New Haven, CT 06520-8059, Connecticut, USA.
Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery , Yale University School of Medicine, 40 Temple Street 5A, New Haven, Connecticut, USA.
F1000Res. 2017 Dec 4;6:2085. doi: 10.12688/f1000research.11314.1. eCollection 2017.
Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease.
基底细胞癌(BCC)是全球最常见的恶性肿瘤,起源于表皮基底层的非角质形成细胞。BCC的发病率每年持续上升,增加了这些癌症的管理负担以及与其治疗相关的发病率。虽然诸如莫氏显微手术和手术切除等外科干预措施是标准治疗方法且治愈率最高,但被批准用于治疗BCC的非手术干预措施的数量仍在不断增加。我们综述了治疗BCC的各种手术和非手术方法,重点关注已被批准用于局部晚期或复发性疾病的靶向分子疗法。